+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Glenmark Pharmaceuticals Ltd (GLENMARK) - Financial and Strategic SWOT Analysis Review

  • ID: 4282150
  • SWOT Analysis
  • 54 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Aurobindo Pharma Ltd
  • Divi's Laboratories Ltd
  • Mylan Laboratories Ltd
  • Mylan NV
  • Pfizer Ltd
  • MORE
Glenmark Pharmaceuticals Ltd (GLENMARK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

Critical Information Included
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Glenmark Pharmaceuticals Ltd (Glenmark) focuses on the discovery of new chemical entities (NCEs) and new biological entities (NBEs). The company's formulations business encompasses therapeutic areas such as dermatology, anti-infective, respiratory, central nervous system, and oncology. It also offers a wide range of generic products. The company manufactures and supplies active pharmaceutical ingredients (APIs). Glenmark developed a proprietary platform, Bispecific Engagement by antibodies based on the T-cell receptor (BEAT) for production of bispecific antibodies. The company markets its products in North America, South America, Asia-Pacific and Africa.

Glenmark Pharmaceuticals Ltd Key Recent Developments

Mar 06, 2019 Glenmark Pharmaceuticals appoints Alessandro Riva as CEO of its new innovation company
Feb 15, 2019 Glenmark Pharmaceuticals to establish new company in US
Feb 14, 2019 Glenmark’s consolidated revenue rises 15.95% to Rs. 25, 550.45 Mn. in Q3 FY 2018 – 19
Dec 19, 2018 Glenmark Pharmaceuticals announces entry into branded dermatology segment in the United States

Key Benefits

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Aurobindo Pharma Ltd
  • Divi's Laboratories Ltd
  • Mylan Laboratories Ltd
  • Mylan NV
  • Pfizer Ltd
  • MORE
Section 1 - About the Company
  • Glenmark Pharmaceuticals Ltd - Key Facts
  • Glenmark Pharmaceuticals Ltd - Key Employees
  • Glenmark Pharmaceuticals Ltd - Key Employee Biographies
  • Glenmark Pharmaceuticals Ltd - Major Products and Services
  • Glenmark Pharmaceuticals Ltd - History
  • Glenmark Pharmaceuticals Ltd - Company Statement
  • Glenmark Pharmaceuticals Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 – Company Analysis
  • Company Overview
  • Glenmark Pharmaceuticals Ltd - Business Description
  • Product Category: Other Operating Revenue
  • Performance
  • Product Category: Sale of Products
  • Performance
  • Product Category: Sale of Services
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: India
  • Performance
  • Geographical Segment: Latin America
  • Performance
  • Geographical Segment: Rest of the World (ROW)
  • Performance
  • Geographical Segment: USA
  • Performance
  • R&D Overview
  • Glenmark Pharmaceuticals Ltd - Corporate Strategy
  • Glenmark Pharmaceuticals Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Glenmark Pharmaceuticals Ltd - Strengths
  • Glenmark Pharmaceuticals Ltd - Weaknesses
  • Glenmark Pharmaceuticals Ltd - Opportunities
  • Glenmark Pharmaceuticals Ltd - Threats
  • Glenmark Pharmaceuticals Ltd - Key Competitors
Section 3 – Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
  • Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
  • Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
  • Glenmark Pharmaceuticals Ltd, Recent Deals Summary
Section 5 – Company’s Recent Developments
  • Mar 06, 2019: Glenmark Pharmaceuticals appoints Alessandro Riva as CEO of its new innovation company
  • Feb 15, 2019: Glenmark Pharmaceuticals to establish new company in US
  • Feb 14, 2019: Glenmark’s consolidated revenue rises 15.95% to Rs. 25,550.45 Mn. in Q3 FY 2018 – 19
  • Dec 19, 2018: Glenmark Pharmaceuticals announces entry into branded dermatology segment in the United States
  • Nov 13, 2018: Glenmark’s consolidated revenue rises 14.39% to Rs. 25,813.32 Mn. in Q2 FY 2018–19
  • Nov 07, 2018: Glenmark Pharmaceuticals Announces Decision to Launch Phase 1 Trial in Solid Tumors for its CD38xCD3 Bispecific Antibody GBR 1342 Based on Human Translational Data
  • Oct 30, 2018: Glenmark Pharmaceuticals celebrates the inauguration of its U.S. manufacturing site in Monroe, North Carolina
  • Oct 18, 2018: Data on Glenmark Pharmaceuticals'' GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody in Development for the Treatment of Moderate-to-Severe Atopic Dermatitis, to be Presented at the Fall Clinical Dermatology Conference
Section 6 – Appendix
  • Methodology
  • Ratio Definitions
  • About the Author
  • Contact Us
  • Disclaimer
List of Tables
  • Glenmark Pharmaceuticals Ltd, Key Facts
  • Glenmark Pharmaceuticals Ltd, Key Employees
  • Glenmark Pharmaceuticals Ltd, Key Employee Biographies
  • Glenmark Pharmaceuticals Ltd, Major Products and Services
  • Glenmark Pharmaceuticals Ltd, History
  • Glenmark Pharmaceuticals Ltd, Other Locations
  • Glenmark Pharmaceuticals Ltd, Subsidiaries
  • Glenmark Pharmaceuticals Ltd, Key Competitors
  • Glenmark Pharmaceuticals Ltd, Ratios based on current share price
  • Glenmark Pharmaceuticals Ltd, Annual Ratios
  • Glenmark Pharmaceuticals Ltd, Annual Ratios (Cont...1)
  • Glenmark Pharmaceuticals Ltd, Annual Ratios (Cont...2)
  • Glenmark Pharmaceuticals Ltd, Interim Ratios
  • Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
  • Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
  • Glenmark Pharmaceuticals Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Glenmark Pharmaceuticals Ltd, Performance Chart (2014 - 2018)
  • Glenmark Pharmaceuticals Ltd, Ratio Charts
  • Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
  • Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Aurobindo Pharma Ltd
  • Divi's Laboratories Ltd
  • Dr. Reddy's Laboratories Ltd
  • Emcure Pharmaceuticals Ltd
  • Mylan Laboratories Ltd
  • Mylan NV
  • Pfizer Ltd
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
Note: Product cover images may vary from those shown
Adroll
adroll